This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Tarn C , Rink L , Merkel E , Flieder D , Pathak H , Koumbi D , Testa JR , Eisenberg B , von Mehren M , Godwin AK
Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors
Proc Natl Acad Sci U S A. 2008 Jun 17;105(24) :8387-92
PMID: 18550829 PMCID: PMC2448846
AbstractA subset of gastrointestinal stromal tumors (GISTs) lack gain-of-function mutations in c-KIT and PDGFRalpha. These so-called wild-type (WT) GISTs tend to be less responsive to imatinib-based therapies and have a poor prognosis. We identified amplification of IGF1R in a SNP analysis of GIST and thus studied its potential as a therapeutic target in WT and mutant GIST. Expression of IGF1R and downstream effectors in clinical GIST samples was examined by using immunoblots and immunohistochemistry. The roles of IGF1R signaling in GIST and viability were analyzed by using NVP-AEW541, an inhibitor of IGF1R, alone and in combination with imatinib, or via siRNA silencing of IGF1R. IGF1R was strongly overexpressed, and IGF1R amplification was detected at a significantly higher frequency in WT GISTs, including a pediatric WT GIST, compared with mutant GISTs (P = 0.0173 and P = 0.0163, respectively). Inhibition of IGF1R activity in vitro with NVP-AEW541 or down-regulation of expression with siIGF1R led to cytotoxicity and induced apoptosis in GIST cell lines via AKT and MAPK signaling. Combination of NVP-AEW541 and imatinib in GIST cell lines induced a strong cytotoxicity response. Our results reveal that IGF1R is amplified and the protein is overexpressed in WT and pediatric GISTs. We also demonstrate that the aberrant expression of IGF1R may be associated with oncogenesis in WT GISTs and suggest an alternative and/or complementary therapeutic regimen in the clinical management of all GISTs, especially in a subset of tumors that respond less favorably to imatinib-based therapy.
NotesTarn, Chi Rink, Lori Merkel, Erin Flieder, Douglas Pathak, Harsh Koumbi, Daphne Testa, Joseph R Eisenberg, Burton von Mehren, Margaret Godwin, Andrew K 5P30CA06927-44/CA/NCI NIH HHS/United States CA009035-31/CA/NCI NIH HHS/United States CA106588/CA/NCI NIH HHS/United States CA77429/CA/NCI NIH HHS/United States P30 CA06927/CA/NCI NIH HHS/United States Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States Proceedings of the National Academy of Sciences of the United States of America Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8387-92. Epub 2008 Jun 11.